238 related articles for article (PubMed ID: 21750122)
1. Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.
Cole LE; Mann BJ; Shirey KA; Richard K; Yang Y; Gearhart PJ; Chesko KL; Viscardi RM; Vogel SN
J Leukoc Biol; 2011 Oct; 90(4):787-97. PubMed ID: 21750122
[TBL] [Abstract][Full Text] [Related]
2. Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity.
Cole LE; Elkins KL; Michalek SM; Qureshi N; Eaton LJ; Rallabhandi P; Cuesta N; Vogel SN
J Immunol; 2006 Jun; 176(11):6888-99. PubMed ID: 16709849
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge.
Cole LE; Yang Y; Elkins KL; Fernandez ET; Qureshi N; Shlomchik MJ; Herzenberg LA; Herzenberg LA; Vogel SN
Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4343-8. PubMed ID: 19251656
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages.
Cole LE; Shirey KA; Barry E; Santiago A; Rallabhandi P; Elkins KL; Puche AC; Michalek SM; Vogel SN
Infect Immun; 2007 Aug; 75(8):4127-37. PubMed ID: 17517865
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain.
Medina EA; Morris IR; Berton MT
J Immunol; 2010 Dec; 185(12):7562-72. PubMed ID: 21098227
[TBL] [Abstract][Full Text] [Related]
6. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
[No Abstract] [Full Text] [Related]
7. Critical role of IL-25-ILC2-IL-5 axis in the production of anti-Francisella LPS IgM by B1 B cells.
Barbosa CHD; Lantier L; Reynolds J; Wang J; Re F
PLoS Pathog; 2021 Aug; 17(8):e1009905. PubMed ID: 34449811
[TBL] [Abstract][Full Text] [Related]
8. TLR-dependent control of Francisella tularensis infection and host inflammatory responses.
Abplanalp AL; Morris IR; Parida BK; Teale JM; Berton MT
PLoS One; 2009 Nov; 4(11):e7920. PubMed ID: 19936231
[TBL] [Abstract][Full Text] [Related]
9. Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling.
Cole LE; Laird MH; Seekatz A; Santiago A; Jiang Z; Barry E; Shirey KA; Fitzgerald KA; Vogel SN
J Leukoc Biol; 2010 Feb; 87(2):275-81. PubMed ID: 19889726
[TBL] [Abstract][Full Text] [Related]
10. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
[TBL] [Abstract][Full Text] [Related]
11. Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways.
Cole LE; Santiago A; Barry E; Kang TJ; Shirey KA; Roberts ZJ; Elkins KL; Cross AS; Vogel SN
J Immunol; 2008 May; 180(10):6885-91. PubMed ID: 18453609
[TBL] [Abstract][Full Text] [Related]
12. FcγR mediates TLR2- and Syk-dependent NLRP3 inflammasome activation by inactivated Francisella tularensis LVS immune complexes.
Duffy EB; Periasamy S; Hunt D; Drake JR; Harton JA
J Leukoc Biol; 2016 Dec; 100(6):1335-1347. PubMed ID: 27365531
[TBL] [Abstract][Full Text] [Related]
13. Kdo hydrolase is required for Francisella tularensis virulence and evasion of TLR2-mediated innate immunity.
Okan NA; Chalabaev S; Kim TH; Fink A; Ross RA; Kasper DL
mBio; 2013 Feb; 4(1):e00638-12. PubMed ID: 23404403
[TBL] [Abstract][Full Text] [Related]
14. Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intra-macrophage bacterial replication.
Collazo CM; Sher A; Meierovics AI; Elkins KL
Microbes Infect; 2006 Mar; 8(3):779-90. PubMed ID: 16513388
[TBL] [Abstract][Full Text] [Related]
15. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.
Dreisbach VC; Cowley S; Elkins KL
Infect Immun; 2000 Apr; 68(4):1988-96. PubMed ID: 10722593
[TBL] [Abstract][Full Text] [Related]
16. Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism.
Shirey KA; Cole LE; Keegan AD; Vogel SN
J Immunol; 2008 Sep; 181(6):4159-67. PubMed ID: 18768873
[TBL] [Abstract][Full Text] [Related]
17. Production of IFN-γ by splenic dendritic cells during innate immune responses against Francisella tularensis LVS depends on MyD88, but not TLR2, TLR4, or TLR9.
De Pascalis R; Rossi AP; Mittereder L; Takeda K; Akue A; Kurtz SL; Elkins KL
PLoS One; 2020; 15(8):e0237034. PubMed ID: 32745117
[TBL] [Abstract][Full Text] [Related]
18. Francisella tularensis LPS induces the production of cytokines in human monocytes and signals via Toll-like receptor 4 with much lower potency than E. coli LPS.
Dueñas AI; Aceves M; Orduña A; Díaz R; Sánchez Crespo M; García-Rodríguez C
Int Immunol; 2006 May; 18(5):785-95. PubMed ID: 16574669
[TBL] [Abstract][Full Text] [Related]
19. Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.
Chiavolini D; Weir S; Murphy JR; Wetzler LM
Clin Vaccine Immunol; 2008 Sep; 15(9):1322-9. PubMed ID: 18614668
[TBL] [Abstract][Full Text] [Related]
20. Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection.
Mohapatra SK; Cole LE; Evans C; Sobral BW; Bassaganya-Riera J; Hontecillas R; Vogel SN; Crasta OR
BMC Infect Dis; 2010 Jan; 10():10. PubMed ID: 20082697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
